Cooper Financial Group Purchases Shares of 4,278 Qiagen N.V. $QGEN

Cooper Financial Group purchased a new stake in shares of Qiagen N.V. (NYSE:QGEN) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 4,278 shares of the company’s stock, valued at approximately $206,000.

A number of other institutional investors have also bought and sold shares of the company. Wellington Management Group LLP boosted its position in Qiagen by 12.2% during the first quarter. Wellington Management Group LLP now owns 24,438,441 shares of the company’s stock valued at $972,191,000 after acquiring an additional 2,656,136 shares during the last quarter. Deutsche Bank AG boosted its position in shares of Qiagen by 57.5% during the 1st quarter. Deutsche Bank AG now owns 4,491,131 shares of the company’s stock worth $180,319,000 after purchasing an additional 1,639,621 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Qiagen by 3,030.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 4,470,728 shares of the company’s stock worth $179,501,000 after purchasing an additional 4,327,934 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its position in shares of Qiagen by 4.7% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 2,445,641 shares of the company’s stock worth $96,605,000 after purchasing an additional 109,481 shares in the last quarter. Finally, Caisse Des Depots ET Consignations boosted its position in shares of Qiagen by 7.3% during the 1st quarter. Caisse Des Depots ET Consignations now owns 1,345,657 shares of the company’s stock worth $53,374,000 after purchasing an additional 91,357 shares in the last quarter. Institutional investors own 70.00% of the company’s stock.

Qiagen Trading Down 0.1%

NYSE:QGEN opened at $46.26 on Friday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.35 and a current ratio of 1.61. The firm has a market cap of $10.28 billion, a price-to-earnings ratio of 27.33, a price-to-earnings-growth ratio of 2.44 and a beta of 0.66. Qiagen N.V. has a 52 week low of $37.63 and a 52 week high of $51.88. The firm has a 50-day moving average price of $47.53 and a two-hundred day moving average price of $45.19.

Qiagen (NYSE:QGEN) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $0.60 EPS for the quarter, meeting the consensus estimate of $0.60. The firm had revenue of $533.54 million during the quarter, compared to analyst estimates of $523.97 million. Qiagen had a net margin of 18.30% and a return on equity of 14.77%. The company’s revenue for the quarter was up 7.7% on a year-over-year basis. During the same quarter last year, the business posted $0.55 EPS. Qiagen has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. On average, equities analysts expect that Qiagen N.V. will post 2.26 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

QGEN has been the topic of a number of research analyst reports. Wall Street Zen cut shares of Qiagen from a “strong-buy” rating to a “buy” rating in a research report on Monday, August 11th. UBS Group increased their price objective on shares of Qiagen from $48.00 to $50.00 and gave the stock a “neutral” rating in a research report on Thursday, August 7th. Barclays set a $53.00 price objective on shares of Qiagen and gave the stock an “overweight” rating in a research report on Thursday. Cowen reissued a “hold” rating on shares of Qiagen in a research report on Thursday, August 7th. Finally, Bank of America increased their price objective on shares of Qiagen from $50.00 to $53.00 and gave the stock a “buy” rating in a research report on Thursday, June 26th. Three investment analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat, Qiagen currently has an average rating of “Hold” and a consensus price target of $49.40.

Qiagen Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.